Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "Where To Buy Sedatives"

Looking for quality documents?
external link icon
Repligen to Present at 2015 Leerink Global Healthcare Conference
WALTHAM, Mass., Feb. 4, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that the Company will present at the 2015 Leerink Global Healthcare Conference to be held February 11-12 at the Waldorf Astoria hotel in New York. Management is scheduled to participate in an analyst-moderated "fireside chat" with investors at 2:40 p.m. EST on Thursday, February 12, 2015. A live audio webcast of this discussion will be accessible through the Investor Events section of Company's website. A replay of the webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical
external link icon
Repligen to Present at Stephens Inc. Fall Investment Conference
WALTHAM, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present at the Stephens Fall Investment Conference on Wednesday, November 12 at 10:00 a.m. EST. The conference will be held at the New York Palace Hotel in New York City. An audio-only webcast of Dr. Herlihy's remarks and discussion with the audience will be accessible at the time of the presentation through the Investor Events section of Company's website. A replay of this webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A
external link icon
Repligen to Host Investor & Analyst Event on October 16
- Discussion of Biomanufacturing Trends and Technologies Will be Webcast - WALTHAM, Mass., Oct. 10, 2014 (GLOBE NEWSWIRE) -Repligen Corporation (Nasdaq:RGEN) today announced that the Company will host an Investor & Analyst Event on October 16, 2014 in New York. The event, which will begin at 8:00 a.m. and conclude by 9:30 a.m. (EDT), will feature a presentation by Howard L. Levine, Ph.D., co-founder and President of BioProcess Technology Consultants. Dr. Levine is a recognized thought leader and published expert on the subject of biopharmeceuticals process development and manufacturing. Repligen speakers will include key members of the Company's management team: Walter C. Herlihy, Ph.D., President and CEO; Tony J. Hunt, COO; and Jon K. Snodgres, CFO. Dr. Levine will discuss factors that are driving significant changes in biomanufacturing, and Repligen management will discuss the Company's role in advancing bioprocessing technologies that increase facility efficiency and
external link icon
Repligen Appoints Nicolas M. Barthelemy to Board of Directors
WALTHAM, Mass., June 12, 2014 (GLOBE NEWSWIRE) - Repligen Corporation today announced that it has elected life sciences and biopharmaceutical industry veteran Nicolas M. Barthelemy to its Board of Directors. Mr. Barthelemy brings over 20 years of industry experience to the director role, most recently as President, Global Commercial Operations at Life Technologies, a multinational life sciences company whose acquisition by Thermo Fisher Scientific was completed earlier this year. Mr. Barthelemy is particularly accomplished in the areas of commercial expansion and global market development, supported by his strong background in biologic drug manufacturing and supply chain management. "I am pleased to welcome Nicolas Barthelemy as a fitting addition to the Repligen Board," said Walter C. Herlihy, President and Chief Executive Officer of Repligen. "Mr. Barthelemy's input will have immediate value as we expand our commercial organization to market our growing portfolio of proprietary
external link icon
Repligen to Present at Jefferies 2014 Global Healthcare Conference
WALTHAM, Mass., May 28, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Jefferies 2014 Global Healthcare Conference at 8:00 a.m. EDT on Wednesday, June 4. The conference will be held June 2-5, 2014 at The Grand Hyatt New York. A live audio webcast of the Repligen presentation will be accessible through the Investor Relations section of Company website at www.repligen.com ; see News & Events, Events & Presentations. A replay of the webcast will also available for a period of time following the conference. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biologic drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies
external link icon
Repligen to Present at the Stifel Healthcare Conference 2013
WALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Stifel Healthcare Conference on Wednesday, September 11, 2013 at 3:50 p.m. EDT. The annual conference will take place September 11-12 at the Four Seasons Hotel in Boston. The Repligen presentation will be webcast live and can be accessed through the Investors section of Company's website at www.repligen.com . The webcast and slide presentation will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading
external link icon
Repligen To Report Third Quarter of 2012 Financial Results
- Webcast and Conference Call to Be Held Thursday, November 8, 9:00 a.m. EST - Repligen Corporation (NASDAQ:RGEN) today announced that it will report financial results for the third quarter of 2012 before the NASDAQ Global Market opens on Thursday, November 8. The earnings press release will be followed by a conference call and webcast at 9:00 a.m. EST. The event will be hosted by Walter C. Herlihy, Ph.D., President and CEO of Repligen, who will discuss financial results for the third quarter and year-to-date and provide a corporate update. Repligen’s third quarter conference call will be accessible by dialing (800) 260-8140 for domestic callers or (617) 614-3672 for international callers. Dial-in participants must provide the passcode 85324503 . Alternatively, an audio webcast will be accessible via the Investors section of Repligen’s website www.repligen.com . Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in
external link icon
Repligen to Present at Stifel Nicolaus Healthcare Conference 2012
- Thursday, September 6, 10:20 a.m. EDT - Repligen Corporation (NASDAQ:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will be presenting at the upcoming Stifel Nicolaus Healthcare Conference in Boston. Dr. Herlihy will provide a corporate update and discuss the Company’s recent decision to focus corporate strategy on the growth of its bioprocessing business. The Repligen presentation is scheduled for Thursday, September 6, 2012 at 10:20 a.m. EDT. A live webcast and subsequent archived replay of the presentation will be available through the Investors section of Repligen’s corporate website at www.repligen.com . To access the live webcast, please log on through the Company’s website approximately 15 minutes prior to the presentation. About Repligen Corporation Repligen Corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. Our
external link icon
Repligen To Report Second Quarter of 2012 Financial Results
- Webcast and Conference Call to Be Held Thursday, August 2, 8:30 a.m. EDT - Repligen Corporation (NASDAQ:RGEN) today announced it will report financial results for the second quarter of 2012 before the NASDAQ Global Market opens on Thursday, August 2. The earnings press release will be followed by a conference call and webcast at 8:30 a.m. EDT. The call will be hosted by Walter C. Herlihy, Ph.D., President and CEO of Repligen, to discuss financial results and highlights for the second quarter and to provide a corporate update. The live conference call can be accessed by dialing (866) 543-6407 for domestic callers or (617) 213-8898 for international callers. Dial-in participants must provide the passcode 51406171 . The webcast can be accessed at the Investors section of Repligen’s website www.repligen.com . Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617)
external link icon
Repligen to Present at JMP Securities Healthcare Conference 2012
Repligen Corporation (NASDAQ:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present a corporate update at the JMP Securities Healthcare Conference 2012 in New York. The Repligen presentation is scheduled for Friday, July 13, at 11:00 a.m. EDT. A live webcast and subsequent archived replay of the presentation will be available through the Investors section of Repligen’s corporate website at www.repligen.com . To access the live webcast, please log on through the Company’s website approximately 15 minutes prior to the presentation. About Repligen Corporation
Repligen Corporation is a leading supplier of critical biologic products used to manufacture biologic drugs. Repligen also applies its expertise in biologic product development to RG1068, a synthetic hormone being developed as a novel imaging agent for the diagnosis of a variety of pancreatic diseases. In addition, the Company has two central nervous system (CNS) rare disease